The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

Autoimmune Technologies LLC develops medical diagnostic tests. It explores disease mechanisms, and investigates therapies for autoimmune diseases, disorders and anti-viral drugs. The company was founded in 1995 and is headquartered in New Orleans, LA.

Part of Abbott Laboratories, Abbott Biologicals BV is a company headquartered in Weesp, the Netherlands, that develops pharmaceutical preparations and substances.

Part of ISHIHARA SANGYO KAISHA LTD., GenomIdea, Inc. is a Japanese company located in Ibaraki. The firm engages in biopharmaceutical products development and distribution. On January 31, 2013 ISHIHARA SANGYO KAISHA LTD. acquired GenomIdea, Inc. from AnGes, Inc.

Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Valo Therapeutics Oy is a company headquartered in Helsinki, Finland, with subsidiaries in the United Kingdom. The firm develops novel immunotherapies for cancer and infectious disease. It was founded in 2016. Paul Grant Higham is the CEO, in this role since 2020.\nThe company says this about itself: Valo Therapeutics Oy (Helsinki) is an immunotherapy company developing antigen-coated oncolytic viruses as therapeutic vaccines against cancer. The ValoTx lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into powerful activators of systemic anti-tumor cytotoxic T-cell immunity without the need to generate and manufacture multiple genetically modified viruses. PeptiCRAd-1 is the company’s lead product made up of its virus VALO-D102 coated with MAGE-A3 and NY-ESO-1 peptides. The company is also developing other neoantigen strategies.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

MicroGeneSys, Inc. is a private company headquartered in Meriden, CT. The firm engages in engineering and management services.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Part of Mymetics Corp., Bestewil Holding BV is a company headquartered in Leiden, the Netherlands, focused on pharmaceutical preparations. On April 10, 2009 Mymetics Corp. acquired Bestewil Holding BV from Norwood Immunology Pty Ltd for $9.41 million.

Develops therapeutic products in oncology and infectious diseases

Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.